Skip to Main Content

Paper Details

Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Oncologist
18
2021
Author NameAffiliation
Pavlos MsaouelThe University of Texas MD Anderson Cancer Center
Pavlos MsaouelThe University of Texas MD Anderson Cancer Center
  • 1 - 2

Datasets

Release 1.2